Cancer treatment and research
-
Using high-dose methotrexate, doxorubicin, and cisplatinum (or BCD) for adjuvant chemotherapy in osteosarcoma of the extremities, we achieved 8-year metastasis-free survival rates of 60-70%. No relapse has been observed after that time. A dose of 12 g/m2 of high-dose methotrexate seems superior to 6 g; doxorubicin was found to be indispensable for efficient therapy and administering ifosfamide in addition seemed to be beneficial. ⋯ Given the limited number of effective drugs, it might be difficult to further improve the cure rate and also to diminish late toxicity. Exploration of the most effective but least toxic mode of drug administration might be one possibility. Another might be reduction of the cumulative doses and therapy duration, while simultaneously increasing the dose rate.
-
Review Randomized Controlled Trial Clinical Trial
Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
The multi-institutional osteosarcoma study: an update.
-
Review Multicenter Study Clinical Trial
An update of Scandinavian studies of osteosarcoma.